Can Mouth Infection Bring Up Blood Pressure

Keys to understanding the law of prepaid

rejection is prevented members by age or preexisting conditions; standard shafts

THE NATION Photo / Marcelo Gomez

The law governing the prepaid system was approved yesterday by a large majority in Congress. Originally voted in the House of Representatives unanimously and amended in the Senate this year with the agreement of all blocks, yesterday won 190 votes in favor, none against and 29 abstentions mostly members of Pro and the Civic Coalition (CC).

The reform provides new benefits for users, but is strongly opposed by the largest companies in the sector.

In 31 articles, the law introduces the following modifications:

• obliges companies to cover medical insurance plans of care, the Compulsory Medical Plan (PMO) and the system with basic services for people with disabilities.

The

• benefits companies may not be less than the PMO.

• performance contracts must be approved by the Ministry of Health, and users can terminate them at any time.

• Age can not be a litmus test for admissions.

• Companies can not refuse membership to people with preexisting conditions, but applying differential values \u200b\u200bproperly justified and approved.

• Those over 65 years, ten years old in coverage, they can not increase the quota.

• mechanisms to be imposed from the government authorizing or not the increase in quotas.

• contracts between companies and users can not include periods of absence or wait for those features that are included in the PMO.

Best Highlights For Damaged Hair

Free workshop on low vision

Directed patients with macular diseases, family and friends, the ophthalmology department of the Hospital Italiano de Buenos Aires organized a free workshop on low vision. It can converse with specialists. The appointment will be on 13 May at 17, Potosí 4296, Capital. Information and registration: (011) 4959-0348, or email @ hospitalitaliano.org.a informes.docencia

List Of Bachelors Trips

Novartis says study shows Lucentis is safer than

Swiss drugmaker Novartis AG said Wednesday that a new study shows that its ophthalmic drug Lucentis is safer than Avastin cancer drug for the treatment of macular degeneration.

Novartis said the analysis conducted by the Johns Hopkins University represents the best available information from the comparison of Roche's Avastin and Lucentis.

"These data contribute to the existing body of evidence suggests that the risk of death and cerebrovascular accident (CVA) would be greater in patients treated with Avastin compared to Lucentis," said Novartis.

Novartis and its partner Roche generated each about 1,500 million dollars in sales last year with Lucentis, and some analysts believe could become a drug in excess of 10,000 million dollars sales.

"Now more than ever it is clear that Lucentis and Avastin are different, and Novartis believes that Lucentis is the best therapy for patients," said Trevor Mundel, head of global development at Novartis Pharma.

Last week, U.S. researchers reported on a study by the National Eye Institute that Avastin worked just as Lucentis in treating vision loss caused by macular degeneration, but had more side effects.

The results were considered a threat to the millions of dollars from sales of Lucentis they hope to collect Roche, which sells the medicine in the United States, and Novartis, which markets the rest of the world, since most doctors prefer Avastin, which is much cheaper.

Avastin costs $ 50 per injection, compared with nearly $ 2,000 it costs to Lucentis.

But doctors still hesitate to prescribe Avastin after a study showed higher rates of severe systemic side effects, which require hospitalization.

Christian Wedding Invitations Wording In Spanish

Avastin Avastin is as good as Lucentis to treat wet macular degeneration.

The results of the National Eye Institute study were released a week ago. The study, "Comparison of age-related macular degeneration treatment trials (CATT) "compared the two drugs head to head in a year long study in which about 1200 patients.

The study is important because Lucentis and Avastin are produced by the same company, Genentech. Lucentis is approved by the FDA for the treatment of wet macular degeneration, however, Avastin is the standard of care.

Lucentis has costs of 40 to 50 times more than Avastin.

In short, most retina specialists in the United States have been using the cheaper alternative as we have suspected that the two are equally effective in treating the disease, but at a fraction of the cost.

The CATT report compared the two injections in a variety of dosing schedules every four weeks versus "as needed." The results indicate that the two drugs are equally effective whether given regularly or as needed. "

The main difference between the two drugs is cost. Lucentis costs $ 2000, while Avastin is approximately $ 50 or less. Avastin is not sold directly to ophthalmologists by Genetech. capitalization pharmacies buy drugs, a chemotherapy agent, and divide it into smaller portions for injection for our use.

side effects of both drugs were similar. Both seem to be very confident after a year of study. Patients will be followed by more data on long-term security.

What does this mean?
This may be the end to the dispute between Avastin vs. Lucentis.
Finally, there is evidence that confirms what many of us have been suspecting ... cheaper drug is as good as the more expensive drug!
The economic impact of this study will be powerful.
Better yet, the study showed that the administration "as needed" may be as good as a regimented therapy regular dosing every 4-6 weeks.

"Randy" Randall V.
Wong, MD
Ophthalmologist, retina specialist
Fairfax, Virginia
http://www.retinaeyedoctor.com/